Global Lung Cancer Market: Information by Type (SCLC and NSCLC), Treatment (Surgery, Chemotherapy, Radiotherapy, Photodynamic Therapy (PDT) and Laser Therapy), End User (Hospital & Clinics, Cancer Research Centers and Laboratories) and Region (North America, Europe, Asia-Pacific and Middle East & Africa) – Forecast till 2023
Market Highlights
Lung cancer is a malignant lung tumor characterized by uncontrolled cell growth in lung tissue with symptoms such as coughing, weight loss, fatigue and chest pain. The two types of lung cancers are small-cell lung carcinoma (SCLC) and non-small-cell lung carcinoma (NSCLC). The NSCLC type accounts for almost 80% of the cancers with NSCLC representing the remaining. The cure rates for the two types of lung cancers exchange their positions with the SCLC being the most malignant. The cure rates also depend on the stage of cancer detection with rates varying by 55% for first stage to just 1% for stage four.
Get Free Sample Lung Cancer Market Research Report – Global Forecast To 2023” of 116 pages supported by 89 tables and 35 figures at: https://www.marketresearchfuture.com/sample_request/1185
Almost 85% of cases of lung cancer are due to long-term tobacco smoking. Cigarette smoke contains at least 73 known carcinogens. Other factors causing lung cancer are genetic factors and exposure to triggers and carcinogens such as radon gas, asbestos, radioactive materials, second-hand smoke, or air pollution. It has also been demonstrated that passive smokers have a 20–30% increase in risk.
The treatments for lung cancer include surgery, chemotherapy, and radiotherapy with NSCLC responding better to surgery and SCLC usually responding better to chemotherapy and radiotherapy. The main drivers of lung cancer are the growing environmental pollution and smoking. The rise in the cases of lung cancers in females due to rising number of female smokers will drive the market up. Another driver is the greater screening rates with a sizable portion of lung cancer are detected during screening for other diseases.
Global Lung Cancer Market:
In the coming years, it is expected that the global Lung Cancer market will advance with higher growth rate as compared to previous years. Factors such as Smoking, Rising cases of infections, Rising rates of fast growing lung cancer are driving the growth of the global lung cancer market.
The major participants of this market are F. Hoffmann-La Roche AG, Novartis, PFIZER INC, Merck & Co., Inc, BRISTOL-MYERS SQUIBB, ELI Lilly and Company, Sanofi and others. among others.
Key Updates
- In February 2015, F. Hoffmann-La Roche Ltd acquired Signature Diagnostics AG (Signature), a privately held company based in Potsdam, Germany.
- In March 2016, Novartis AG’s cancer drug got FDA’s principal biosimilar affirmation. Federal regulators have permitted the first biosimilar drug to be sold in the US under a program intended to branch a new market of lower-cost substitutes to some of the most expensive treatments in healthcare. This approval of biosimilars will help many patients who need these treatments.
- In August 2016, the FDA approved Pfizer’s TROXYCA ER extended-release capsules CII for pain management. This drug was used for abuse-deterrent properties for the management of pain and helped Pfizer to improve its goodwill and sales with this new product.
Segmentation:
Global Lung Cancer Market has been segmented on the basis of types which comprises of push button Lung Cancer, pressure activated Lung Cancer and side button Lung Cancer. On the basis of end user, it comprises of hospitals & clinics, diagnostic centers and pathology laboratories, home diagnostics and other end users.
Regional Analysis:
The global market for Lung Cancer is growing steadily. The global lung cancer market on the basis of region comprises of North America, Europe, Asia Pacific and Middle East & Africa. The global market for Lung Cancer is growing with the CAGR of 13.5% during the forecast period from 2017-2023. NSCLC is the most common type of lung cancer globally. The global Lung Cancer market reached USD 36929.8 million in 2023 from 15219.7 million in 2016. Europe region captured the second largest market globally and is expected to reach USD 8,536.3 million by 2023 due to the growing demand and need for lung cancer drugs, and the growing prevalence of lung cancer.
Browse More Information On This Report at: https://www.marketresearchfuture.com/reports/lung-cancer-market-1185
About Market Research Future:
At Market Research Future (MRFR), we enable our customers to unravel the complexity of various industries through our Cooked Research Report (CRR), Half-Cooked Research Reports (HCRR), Raw Research Reports (3R), Continuous-Feed Research (CFR), and Market Research & Consulting Services.
MRFR team have supreme objective to provide the optimum quality market research and intelligence services to our clients. Our market research studies by products, services, technologies, applications, end users, and market players for global, regional, and country level market segments, enable our clients to see more, know more, and do more, which help to answer all their most important questions.
In order to stay updated with technology and work process of the industry, MRFR often plans & conducts meet with the industry experts and industrial visits for its research analyst members.
Contact
Akash Anand,
Market Research Future
Office No. 528, Amanora Chambers
Magarpatta Road, Hadapsar,
Pune – 411028
Maharashtra, India
+1 646 845 9312
